论文部分内容阅读
体外实验已证实5-氟尿嘧啶(5-FU)、叶醛酸(LV)和顺铂具有协同抗人结肠癌细胞株作用。作者研究这3种药物联合治疗进展期结肠癌的疗效。患者和方法经组织学确诊的进展期或转移性结肠腺癌且不能手术治疗的患者59例,ECOG机能分期为0期10例,1期29例,2期12例和3期8例;曾用5-FU治疗的12例;癌原发灶在结肠的32例,直肠27例;组织学分级为G_19例,G_228例,G_37例和未分级15例;癌转移至肝34例,肺23例,腹部或盆腔30例,其他13例;癌转移至一处的28例,多处的31例。全部患者治疗前实验室检查包括肾功(血肌酐<1.5mg/dl),肝功(血胆红素<2.0mg/dl),骨髓象(WBC>4.0×10~9/L,血小板>125×10~9/L)。疗程为4日,间隔4周,持续治疗
In vitro experiments have demonstrated that 5-fluorouracil (5-FU), levulinic acid (LV) and cisplatin have a synergistic effect against human colon cancer cell lines. The authors studied the efficacy of these three drugs in the treatment of advanced colon cancer. Patients and Methods Fifty-nine patients with advanced histopathologically diagnosed or metastatic adenocarcinoma of the colon and who could not be treated surgically, ECOG functional staging was 10 patients in stage 0, 29 in stage 1, 12 in stage 2, and 8 in stage 3; Twenty-two patients treated with 5-FU; 32 primary tumors in the colon and 27 rectums; histological grades were G 19 cases, G 228 cases, G 37 cases and ungraded 15 cases; carcinoma metastasis to liver 34 cases, lung 23 cases. Cases, 30 cases of abdominal or pelvic, other 13 cases; 28 cases of cancer metastasis to one place, multiple 31 cases. Pre-treatment laboratory examinations for all patients included renal function (creatinine <1.5 mg/dl), liver function (blood bilirubin <2.0 mg/dl), bone marrow morphus (WBC> 4.0 x 10-9/L, platelets> 125 ×10~9/L). Treatment is 4 days, interval 4 weeks, continuous treatment